Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation.
Some pathogenic bacteria form thick capsules that both block immune responses through inhibition of complement deposition and phagocytosis and stimulate a weak response resulting from a lack of T-cell involvement. Contrary to this model, capsular polysaccharides from 23 serotypes of Streptococcus pneumoniae have been successfully used in a multivalent vaccine in the absence of a carrier protein. Furthermore, type I pneumococcal polysaccharide (Sp1) has been shown to activate T cells in vivo and in vitro via an uncharacterized mechanism. In the present report, we demonstrate that Sp1 utilizes the major histocompatibility complex (MHC) class II pathway in antigen-presenting cells (APCs) for processing and presentation. APCs internalize and process Sp1 through a nitric oxide-dependent mechanism and, once inside the cell, it associates with MHC II proteins in an H-2M-dependent manner that leads to in vivo T-cell activation. These results establish that Sp1 activates T cells which can lead to abscess formation in mice through an H-2M-dependent polysaccharide antigen presentation pathway in APCs, potentially contributing to pneumococcal polysaccharide vaccine efficacy through the recruitment of T-cell help.
Velez
Christopher D
CD
Department of Medicine, Channing Laboratory, Harvard Medical School, Boston, MA, USA.
Lewis
Colleen J
CJ
Kasper
Dennis L
DL
Cobb
Brian A
BA
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D001667:Binding, Competitive / Q000276:immunology; D002478:Cells, Cultured; D011992:Endosomes / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000276:immunology*; D010084:Oxidation-Reduction; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D015398:Signal Transduction / Q000276:immunology; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000949:Histocompatibility Antigens Class II; D011135:Polysaccharides, Bacterial; C450843:pneumococcal polysaccharide type 1; D009569:Nitric Oxide
Carbohydr Res. 1999 Jun 30;319(1-4):141-7
10520262
Carbohydr Res. 1980 Jan 1;78(1):111-7
7351025
Annu Rev Immunol. 1997;15:821-50
9143708
Biochemistry. 1972 Apr 11;11(8):1383-8
4259914
J Immunol. 2002 Dec 1;169(11):6149-53
12444118
Expert Opin Investig Drugs. 1998 Mar;7(3):333-47
15991976
Methods Mol Biol. 2004;271:149-59
15146119
Chem Immunol Allergy. 2005;86:99-119
15976490
Rev Immunogenet. 1999;1(1):60-74
11256573
Nat New Biol. 1973 Sep 5;245(140):12-4
4125593
Infect Immun. 2005 Apr;73(4):2184-9
15784561
J Immunol. 2003 Feb 15;170(4):1958-63
12574364
J Infect Dis. 1983 Dec;148(6):1136-59
6361173
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6584-9
9618455
J Neuroimmunol. 1990 Sep-Oct;29(1-3):49-56
2211988
Cell. 2004 May 28;117(5):677-87
15163414
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9365-70
11470905
Eur J Immunol. 1973 May;3(5):299-306
4586163
Adv Exp Med Biol. 2001;491:453-71
14533815
J Exp Med. 2002 Jul 15;196(2):173-83
12119342
N Engl J Med. 1980 Jul 24;303(4):173-8
6155612
Autoimmunity. 2006 Dec;39(8):691-704
17178566
Nature. 1994 Apr 7;368(6471):551-4
8139689
Rev Infect Dis. 1981 Mar-Apr;3(2):332-41
6973183
J Immunol. 2004 Feb 1;172(3):1483-90
14734725
Science. 1993 Oct 15;262(5132):416-9
8211161
Cell. 2005 Jul 15;122(1):107-18
16009137
Eur J Immunol. 1973 Sep;3(9):531-7
4271925